181 results
8-K
EX-99.1
ACST
Acasti Pharma Inc - Ordinary Shares
21 Jun 24
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
8:00am
announced financial results and business highlights for the year ended March 31, 2024.
"During the past year we continued to execute our focused strategy
8-K
EX-99.1
ACST
Acasti Pharma Inc - Ordinary Shares
1 Apr 24
Regulation FD Disclosure
8:00am
formulations of nimodipine
Strong and multi-layered intellectual property protection strategy Intellectual Property Portfolio GTX-104 received orphan drug
8-K
EX-99.1
ACST
Acasti Pharma Inc - Ordinary Shares
12 Feb 24
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
8:00am
focused strategy around our biggest value driver program GTX-104 and its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). Having
424B3
p7ixwy90qhplc42 tgf
16 Oct 23
Prospectus supplement
4:31pm
8-K
EX-99.1
ag1kb2om
11 Aug 23
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
7:31am
8-K
EX-99.1
9ugjx8pk2or
5 Apr 23
Acasti Announces Appointment of Prashant Kohli as CEO
5:00pm
8-K
mw3g3h4313oqu
5 Apr 23
Acasti Announces Appointment of Prashant Kohli as CEO
5:00pm